Article content material
VANCOUVER, Canada, Jan. 15, 2024 (GLOBE NEWSWIRE) — Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) is proud to introduce Sirona LaboratoriesTM – a wholly-owned subsidiary devoted to maximizing the business potential of its breakthrough anti-aging skincare ingredient, GlycoProteMimTM.
Dr. Howard Verrico, CEO and founding father of Sirona Biochem, expressed his enthusiasm for the main milestone, stating that the institution of Sirona Laboratories is supposed to not simply form the way forward for the corporate, however to revolutionize the worldwide anti-aging skincare market.
Commercial 2
Article content material
Article content material
The announcement follows the latest resolution to trademark GlycoProteMim. The extraordinary outcomes from the energetic ingredient’s medical trials prompted the corporate’s strategic resolution to ascertain Sirona Laboratories, which is able to redefine its trajectory within the skincare business.
“We’ve opted for a plan of action that – is primed to rework, not simply Sirona Biochem’s prospects, however that of the whole anti-aging market. We’re not simply excited about GlycoProteMim’s worth at this time; we wish to construct its legacy and set a world precedent. This isn’t nearly proving its efficacy; it’s about setting a brand new benchmark for anti-aging pores and skin remedies,” Verrico mentioned.
Sirona Biochem is inviting main business gamers to take discover, to associate, and to consider in a future the place GlycoProteMim is the go-to ingredient for pores and skin anti-aging. As a part of the strategic leap into the aesthetic market, Sirona Biochem plans to place itself for optimum development and market enlargement.
Christopher Hopton CPA, Chief Monetary Officer of Sirona Biochem, commented on the launch, stating that the strategic resolution aligns with the corporate’s dedication to shareholder worth, innovation, and market management.
High Tales
Article content material
Commercial 3
Article content material
“By establishing Sirona Laboratories, we aren’t solely maximizing the business potential of GlycoProteMim but additionally guaranteeing sustained development and worth creation for our shareholders,” Hopton added.
Dr. Geraldine Deliencourt-Godefroy, Chief Scientific Officer at Sirona Biochem, expressed pleasure in regards to the scientific prospects. “The corporate’s clinically confirmed science, mixed with the unmet business alternative, positions Sirona Laboratories on the forefront of skincare innovation. We’re desirous to leverage our experience and take GlycoProteMim to new heights, whereas additionally setting a brand new benchmark for anti-aging remedies,” she mentioned.
To assist this bold initiative, the corporate mentioned that it has already recognized a group of seasoned business specialists who will play an important position in steering Sirona Laboratories towards success.
The corporate is actively participating with non-public fairness funds and collaborating with business specialists to develop Sirona Laboratories product line and business technique. The corporate intends to finance the majority of this venture by way of non-public monetary partnerships, whereas leveraging its guardian firm’s mental property.
Commercial 4
Article content material
Sirona Biochem goals to propel the subsidiary, which might be primarily based in Europe, and its energetic ingredient into a brand new period of worldwide recognition. The corporate is inviting the whole pores and skin business and stakeholders to remain tuned for additional updates on the developments and achievements of Sirona Laboratories. Keep up to date by visiting their web site at www.sirona-laboratories.com
About Sirona Biochem:
Sirona Biochem is a number one biotech firm with a proprietary formulation platform expertise. Specializing in beauty components and drug discovery, Sirona Biochem has developed a course of to stabilize carbohydrate molecules, bettering efficacy and security for various purposes.
Sirona’s compounds are licensed to main cosmetics and pharma firms worldwide, in return for licensing charges, milestone funds, and ongoing royalty funds. Sirona’s R&D unit laboratory, TFChem, is positioned in France and is the recipient of a number of French nationwide scientific awards and European Union and French authorities grants.
For extra data, please go to www.sironabiochem.com.
Commercial 5
Article content material
For extra data relating to this press launch, please contact:
Investor Enquiries:
E mail: Data@sironabiochem.com
Neither TSX Enterprise Alternate nor its Regulation Providers Supplier (as that time period is outlined within the insurance policies of the TSX Enterprise Alternate) accepts accountability for the adequacy or accuracy of this launch.
Sirona Biochem cautions you that statements included on this press launch that aren’t an outline of historic details could also be forward-looking statements. Ahead-looking statements are solely predictions primarily based on present expectations and contain recognized and unknown dangers and uncertainties. You might be cautioned to not place undue reliance on these forward-looking statements, which communicate solely as of the date of launch of the related data until explicitly acknowledged in any other case. Precise outcomes, efficiency, or achievement might differ materially from these expressed in, or implied by, Sirona Biochem’s forward-looking statements as a result of dangers and uncertainties inherent in Sirona Biochem’s enterprise together with, with out limitation, statements in regards to the progress and timing of its medical trials; difficulties or delays in growth, testing, acquiring regulatory approval, producing and advertising its merchandise; surprising adversarial negative effects or insufficient therapeutic efficacy of its merchandise that would delay or forestall product growth or commercialization; the scope and validity of patent safety for its merchandise; competitors from different pharmaceutical or biotechnology firms; and its skill to acquire extra financing to assist its operations. Sirona Biochem doesn’t assume any obligation to replace any forward-looking statements besides as required by regulation.
Article content material
Source link
